top of page
  • Completed

NCT02495922: Phase 3 - Elotuzumab in VRD Induction /Consolidation and Len maint in NDMM(GMMG-HD6)

Updated: Sep 15, 2022


A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG-HD6)


German-speaking myeloma multicenter group

(GMMG)

GMMG-HD6 myeloma trial

Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment.


Sponsor

University of Heidelberg Medical Center


Information provided by (Responsible Party)

Prof. Dr. Hartmut Goldschmidt, University of Heidelberg Medical Center


German Study

 

ClinicalTrials.gov Identifier: NCT02495922

Official Title: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma